(Q24244078)

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Scope and impact of financial conflicts of interest in biomedical research: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Overweight as an avoidable cause of cancer in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Rimonabant--a selective CB1 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Body mass index and the prevalence of hypertension and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Appetite suppression and weight loss after the cannabinoid antagonist SR 141716.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Long-term weight loss after diet and exercise: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

The endocannabinoid system and its therapeutic exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Endocannabinoid control of food intake and energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Central obesity and coronary heart disease in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

A prospective study of body mass index, weight change, and risk of stroke in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Cannabinoids and the regulation of ingestive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Body size and fat distribution as predictors of stroke among US men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

7 January 2021

Hazards in subgroups of human obesity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

7 January 2021

Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

7 January 2021

Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006162.PUB2

1 reference

7 January 2021